Laura McMullin of Daiichi Sankyo named as new ABPI Vice-President

The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as Vice-President of the ABPI.

Laura will work closely with ABPI President, Russell Abberley, General Manager of Amgen UK & Ireland, to deliver his presidential priorities and support the ABPI in its mission to make the UK the best place in the world to research, develop and use the medicines and vaccines of the future.

Laura is General Manager at Daiichi Sankyo UK, where she leads the UK organisation in creating and supplying innovative products to help the NHS deliver patient care in the fields of cardiovascular disease and oncology.

Laura McMullin, ABPI Vice-President and Daiichi Sankyo General Manager said: “It’s a privilege to take on this role at such a pivotal time for our industry. I’m looking forward to working closely with Russell and Richard, and the wider ABPI team. Representing a Japanese company with a long-standing commitment to the UK, I am keen to focus on improving the sector environment and patient access to our medicines.”

Russell Abberley, ABPI President and General Manager of Amgen UK & Ireland said: “I am pleased to be working alongside Laura  to drive meaningful progress within the life sciences sector here in the UK.

“Laura is a powerful advocate for improving outcomes for patients, and I know she shares my ambition to make the UK the best place in the world to research, develop and access the medicines and vaccines of the future.”

Richard Torbett, ABPI Chief Executive said: “We’re delighted to welcome Laura as our new Vice-President . She brings deep industry expertise and a strong commitment to improving patient outcomes. I look forward to working with Laura and Russell as we continue to support innovation that delivers real value for patients in the UK.”

Laura’s pharmaceutical career began at AstraZeneca, as part of their graduate scheme where she worked for 3 years across various different functional areas from sales to marketing.

Laura then spent 18 years at Bristol Myers Squibb and held many roles, across various therapeutic areas, of increasing responsibility and was the launch lead across the EMAC & INTERCON markets.

Laura’s interests lie in improving population health through partnerships and to contribute to more efficient and sustainable healthcare systems.